30-Second Executive Brief
Executive Assessment
DexCom functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with a stable competitive position.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Steady
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A continuous glucose monitoring (CGM) company guiding to $5.16-$5.25 billion in 2026 revenue (11-13% growth). DexCom unveiled its next-generation G8 CGM platform at its May 2026 Investor Day with enhanced accuracy and adaptive sensing, and in June 2026 the FDA cleared its Stelo Glucose Biosensor as the first over-the-counter CGM for children ages 2 and older who don't use insulin; the company will cease G6 production starting July 1, 2026 to focus fully on its newer G7 and G8 sensor platforms.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- MobiHealthNews — Dexcom unveils next-generation G8 CGM for real-time glucose monitoringnews
- FDA — FDA clears first over-the-counter continuous glucose monitor for childrencompany
Latest Activity
- FilingDexCom filed an 8-K (items 2.02,9.01)8-K
- FilingDexCom insider selling — $2,408,242 saleForm 4
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding DexCom — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Stelo's pediatric OTC clearance is DexCom's most direct shot at expanding beyond its insulin-using core market
32% confidenceDexCom's Stelo Glucose Biosensor became the first over-the-counter CGM cleared for children ages 2 and older who don't use insulin, while the company simultaneously discontinues G6 production to focus on G7 and the newly unveiled G8 platform for its core insulin-using base.
This is InsightNodes' own interpretive read: DexCom's core prescription CGM business (G6/G7/G8) is capped by the size of the insulin-using diabetic population, while Stelo's OTC, non-insulin-user clearance -- now extended to children -- opens a meaningfully larger total addressable market including pre-diabetic and general wellness-monitoring use cases, directly competing with Abbott's Libre franchise in the same expanding OTC category -- this dual-track strategy (prescription platform upgrades plus OTC market expansion) is a sensible way to grow beyond the ceiling of the traditional insulin-dependent CGM market.
InsightNodes analysis of DexCom 2026 product strategy · Aug 14, 2026
DexCom's Timeline
A sourced, dated history of DexCom's key moments — founding to present.
May 2026 · Unveils next-generation G8 CGM
DexCom announced its G8 continuous glucose monitor at its Investor Day, described as a completely new product platform with enhanced accuracy and adaptive physiologic sensing.
Jun 2026 · FDA clears Stelo for children
The FDA cleared the Dexcom Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children ages 2 and older who do not use insulin.